AUTHORS
Danai Dima, MD, Christelle Colin Leitzinger2, Christopher Ferreri, MD3, Sarvari V. Yellapragada, MD4, Lauren C Peres, PhD, MPH5, Aimaz Afrough, MD6, Andrew J. Portuguese, MD7, Rahul Banerjee, MD, FACP8, Mahmoud R. Gaballa, MD9, James A Davis, PharmD, BCOP10, Omar Alexis Castaneda Puglianini, MD11, Ariel F. Grajales-Cruz, MD12, Shonali Midha, MD13, Binoy Yohannan, MD14, Saurabh Zanwar, MBBS, MD15, Tiffany Richards, PhD, NP16, Bruno Almeida Costa, MD17, Christopher Cahoon, PharmD18, Francesca Cottini, MD19, Megan M Herr, PhD20, Chenyu Lin, MD21, Sneha Purvey, MD22, Marcus Geer, MD23, Ran Reshef, MD24, Asya Varshavsky, MD25, Jennifer Ann Kanakry, MD26, David Oveisi I, MD27, Timothy O'Brien, MD28, Karen Sweiss, PharmD29, Lekha Mikkilineni, MD, MA30, Nisha Joseph, MD31, Veronika Bachanova, MD, PhD32, Shebli Atrash, MD33, Lindsay Fogel, MD34, Ciara Louise L Freeman, MD, PhD35, Saurabh Chhabra, MD, MBBS36, Omar Nadeem, MD37, Noa Biran, MD38, Susan Bal, MD39, Ashley Rosko, MD40, Sikander Ailawadhi, MD41, Peter M Voorhees, MD42, Doug W. Sborov, MD, MS43, Larry D Anderson Jr, MD, PhD44, Frederick L. Locke, MD45, Yi Lin Jr, MD, PhD46, Shaji Kumar, MD47, Luciano J. Costa, MD, PhD48, Cindy Varga, MD49, Surbhi Sidana, MD50, Hira Mian, MD51, Doris K. Hansen, MD52
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Levine Cancer Center, Charlotte, North Carolina, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 UT Southwestern Medical Center, Dallas, Texas, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 University of South Carolina, Charleston, South Carolina, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Dana Farber Cancer Institute, Boston, Massachusetts, United States
14 University of Minnesota, Minneapolis, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 MD Anderson Cancer Center, Houston, Texas, United States
18 Huntsman Cancer Institute University of Utah, Salt Lake, Utah, United States
19 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
20 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
21 Duke Cancer Center, Durham, North Carolina, United States
22 Virginia Commonwealth University, Richmond, Virginia, United States
23 University of Michigan, Ann Arbor, Michigan, United States
24 Columbia University Irving Medical Center, New York, New York, United States
25 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
26 MedStar Georgetown University Hospital, Washington, District of Columbia, United States
27 Cedars-Sinai Medical Center, Los Angeles, California, United States
28 Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
29 University of Illinois, Chicago, Illinois, United States
30 Stanford University School of Medicine, Stanford, California, United States
31 Emory University School of Medicine, Atlanta, Georgia, United States
32 University of Minnesota, Minneapolis, Minnesota, United States
33 Levine Cancer Center, Charlotte, North Carolina, United States
34 Hackensack University Medical Center, Hackensack, New Jersey, United States
35 Moffitt Cancer Center, Tampa, Florida, United States
36 Mayo Clinic, Phoenix, Arizona, United States
37 Dana Farber Cancer Institute, Boston, Massachusetts, United States
38 Hackensack University Medical Center, Hackensack, New Jersey, United States
39 University of Alabama O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
40 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
41 Mayo Clinic, Jacksonville, Florida, United States
42 Levine Cancer Center, Charlotte, North Carolina, United States
43 Huntsman Cancer Institute University of Utah, Salt Lake, Utah, United States
44 UT Southwestern Medical Center, Dallas, Texas, United States
45 Moffitt Cancer Center, Tampa, Florida, United States
46 Mayo Clinic, Rochester, Minnesota, United States
47 Mayo Clinic, Rochester, Minnesota, United States
48 University of Alabama O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
49 Levine Cancer Center, Charlotte, North Carolina, United States
50 Stanford University School of Medicine, Stanford, California, United States
51 McMaster University, Hamilton, Ontario, Canada
52 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction: Patients with t(11;14) multiple myeloma comprise a biologically distinct population whose outcomes following standard-of-care (SOC) ciltacabtagene autoleucel (cilta-cel) remain poorly characterized. Herein, we evaluated the independent impact of t(11;14) on clinical outcomes following SOC cilta-cel.
Methods: We performed a multicenter retrospective analysis of 1506 patients with relapsed-refractory multiple myeloma who received SOC cilta-cel across 23 U.S. institutions. High-risk cytogenetic abnormalities (HRCA) were defined as the presence of t(4;14), t(14;16), and/or del(17p). Baseline characteristics, safety, and efficacy outcomes were compared between patients with and without t(11;14). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariable Cox proportional hazards models identified factors independently associated with PFS and OS. Exploratory subgroup analyses examined survival outcomes according to combinations of t(11;14) and HRCA status.
Results: Among 1506 infused patients, 299 (20%) had t(11;14), including 91 (30%) with and 208 (70%) without coexisting HRCA. Compared with patients without t(11;14), those with t(11;14) were less likely to have HRCA or extramedullary disease (EMD) and had a lower baseline bone marrow plasma cell burden, whereas the median number of prior lines of therapy (4 in both groups) and median follow-up (~13 months) were comparable.
Rates of major toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and non-immune effector cell-associated neurotoxicity (NINT) were similar between groups. Any-grade (grade ≥3) CRS occurred in 74% (3%) and 76% (2%) of patients with and without t(11;14), respectively, while any-grade (grade ≥3) ICANS occurred in 17% (3.7%) and 16% (3.5%), respectively. Best overall response rates were identical in both groups (95%; p>0.9), whereas complete response (CR) or better rates were 77% versus 71% among patients with and without t(11;14), respectively (p=0.07).
In unadjusted analyses, estimated 12-month PFS rates were similar between patients with and without t(11;14) (77% [95% CI=72–82%] versus 75% [95% CI=72–78%]; p=0.17). Corresponding 12-month OS rates were 87% (95% CI=83–91%) and 86% (95% CI=84–88%), respectively (p=0.23). On multivariable analysis adjusting for HRCA, prior BCMA exposure, penta-refractory status, EMD, baseline ferritin, and response to bridging therapy, t(11;14) was not independently associated with either PFS (HR=0.79, 95% CI=0.59–1.05; p=0.11) or OS (HR 0.86, 95% CI=0.59–1.25; p=0.4). In contrast, HRCA, EMD, and elevated baseline ferritin were independently associated with inferior PFS and OS.
Exploratory subgroup analyses based on combined t(11;14) and HRCA status demonstrated that outcomes were primarily determined by coexisting HRCA rather than t(11;14). Multivariable models showed that compared to patients lacking both t(11;14) and HRCA, patients with t(11;14) but not HRCA had better PFS although not statistically significant (HR=0.76, 95% CI=0.44-1.31, p=0.3), while worse PFS was observed for patients with HRCA regardless of t(11;14) status (HRCA without t(11;14): HR=1.70, 95% CI=1.26-2.30, p<0.001; HRCA and t(11;14): HR=1.64, 95% CI=0.97-2.79, p=0.07). Similar findings were observed for OS.
Conclusion: Although t(11;14) was not independently associated with survival after adjustment for established prognostic factors, patients with isolated t(11;14) experienced excellent outcomes following SOC cilta-cel. In contrast, coexisting HRCA abrogated these favorable outcomes irrespective of t(11;14) status, supporting HRCA, rather than t(11;14), as the key prognostic factor following SOC cilta-cel.
DISCLOSURES
Danai Dima, MD: KiTE - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony)